Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.43
-0.14 (-2.13%)
May 19, 2026, 4:00 PM EDT - Market closed
Evolus Revenue
Evolus had revenue of $73.14M in the quarter ending March 31, 2026, with 6.74% growth. This brings the company's revenue in the last twelve months to $301.79M, up 9.56% year-over-year. In the year 2025, Evolus had annual revenue of $297.18M with 11.61% growth.
Revenue (ttm)
$301.79M
Revenue Growth
+9.56%
P/S Ratio
1.40
Revenue / Employee
$862,260
Employees
350
Market Cap
423.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 297.18M | 30.90M | 11.61% |
| Dec 31, 2024 | 266.27M | 64.19M | 31.76% |
| Dec 31, 2023 | 202.09M | 53.47M | 35.98% |
| Dec 31, 2022 | 148.62M | 48.94M | 49.10% |
| Dec 31, 2021 | 99.67M | 43.13M | 76.29% |
| Dec 31, 2020 | 56.54M | 21.62M | 61.89% |
| Dec 31, 2019 | 34.93M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Amphastar Pharmaceuticals | 720.53M |
| Emergent BioSolutions | 676.80M |
| Organogenesis Holdings | 514.70M |
| Ironwood Pharmaceuticals | 361.51M |
| Akebia Therapeutics | 232.40M |
| Canopy Growth | 203.04M |
| Kamada | 181.68M |
EOLS News
- 1 day ago - Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
- 8 days ago - Evolus announces commercial launch of Estyme in Europe - TheFly
- 9 days ago - Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - Business Wire
- 15 days ago - Evolus Earnings Call Transcript: Q1 2026 - Transcripts
- 15 days ago - Evolus Earnings release: Q1 2026 - Filings
- 15 days ago - Evolus Slides: Q1 2026 - Filings
- 15 days ago - Evolus Quarterly report: Q1 2026 - Filings
- 15 days ago - Evolus reports Q1 EPS (16c), consensus (12c) - TheFly